Medication shows promise for patients with severe chronic constipation

The trial involved 38 medical centers and was led by Michael Camilleri, M.D., a Mayo Clinic gastroenterologist. Patients who met the study criteria were randomly assigned to receive either of two dosage levels of prucalopride, a medication that stimulates protein receptors involved in contraction of the colon, or a placebo.

“Many more of the patients taking prucalopride were able to have spontaneous bowel movements without having enemas or taking laxatives, as compared to those who were given placebo,” says Dr. Camilleri. “The time it took to have a first bowel movement was much shorter, and quality of life and other abdominal symptoms also were improved for those taking the study drug.”

Constipation is a common medical problem, affecting about 15 percent of Americans who spend several billion dollars each year on laxatives and other treatments. Prevalence is higher among women and African-Americans and is particularly increased in the elderly. This study involved patients with an extreme but common version of constipation called severe chronic constipation. To
participate, patients had to have at least six months of constipation, defined as an average of fewer than three bowel movements a week. Those who had more than four bowel movements during the two-week “run-in” period before treatment began were not eligible.

“The normal range of bowel movements is anywhere from three per day to three per week,” explains Dr. Camilleri. “The 620 patients studied in this trial were severely constipated, averaging only one bowel movement during the two weeks before entering treatment, and most had struggled with the problem for several years, not merely months.”

The 2 milligram (mg) and 4 mg doses of prucalopride appeared roughly equal in benefit, with about 30 percent of patients averaging three bowel movements per week during the 12-week study. Only 12 percent of patients on placebo averaged three bowel movements per week. Nearly half (47.3 and 46.6 percent, respectively) of the patients taking prucalopride increased their bowel movements by at least one per week, while about a quarter (25.8 percent) of those on placebo had a similar improvement.

The most common adverse effect from the drug was diarrhea, which tended to occur in the early stages of treatment, but most patients later settled into a more normal routine of bowel movements. Increased bowel movements and diarrhea are expected effects of the drug. Only 1.5 percent and 4.4 percent of patients treated with 2 mg and 4 mg of prucalopride, respectively, stopped the drug due to diarrhea. “This suggests that the diarrhea was less bothersome than the constipation had been,” Dr. Camilleri says. Headaches were a less frequent side effect.

Dr. Camilleri says the cardiac risk issues that have been raised about related drugs for constipation including tegaserod, appear to be less of a concern for prucalopride. “Prucalopride is highly selective in its effect, and doesn’t interact significantly with other protein receptors, such as those involved in regulating heart rhythm,” he explains. “We conducted electrocardiogram testing during the study and did not find heart rhythm issues, although two of the three patients who withdrew from the study did have symptoms, palpitations and dizziness that may have been attributable to an effect on the cardiovascular system.”

Source: Mayo Clinic

Family history places women at risk of pelvic organ prolapse, research finds
Pelvic organ prolapse – a tear or weakness in a woman’s pelvic floor muscles that allows her internal organs to fall outside the body – runs in families, a new Saint Louis University study finds.
FDA OKs Relistor for opioid patients
The U.S. Food and Drug Administration has approved Relistor (methylnaltrexone bromide) to help restore bowel function in patients receiving opioids.
Impaired sense of smell may be early indicator of Parkinson's disease
Impaired sense of smell occurs in the earliest stages of Parkinson’s disease (PD) and there is mounting evidence that it may precede motor symptoms by several years, although no large-scale studies had confirmed this. In the first study involving the general population, researchers found that smell impairment can precede the development of PD in men by at least four years. The study is published in the Annals of Neurology.
Eye test peers into heat-related multiple sclerosis symptoms
A bodysuit that heats or cools a patient, combined with painless measurements of eye movements, is providing multiple sclerosis researchers at UT Southwestern Medical Center with a new tool to study the mysterious link between body temperature and severity of MS symptoms.
Warning over severe weight loss caused by chewing gum
In this week’s BMJ, doctors warn of excess sorbitol intake, a widely used sweetener in “sugar-free” products such as chewing gum and sweets.
Constipation most common cause of children's abdominal pain
A new study led by a University of Iowa researcher showed that acute and chronic constipation together accounted for nearly half of all cases of acute abdominal pain in children treated at one hospital.
The pepperoni pizza hypothesis
What's the worst that could happen after eating a slice of pepperoni pizza? A little heartburn, for most people.
Probiotic bacteria don't make eczema better -- and may have side effects
There is no evidence probiotics can relieve the symptoms of eczema, but there is some evidence that they may occasionally cause infections and gut problems. These findings from The Cochrane Library come at a time when use of probiotics to treat eczema is increasing.

Medication shows promise for patients with severe chronic constipation

Related stories:

News discussion: